Skip to main content
Fig. 5 | Respiratory Research

Fig. 5

From: Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial

Fig. 5

Kaplan–Meier plots of time to first CID for three definitionsa. aCID was defined as: a – a first moderate or severe exacerbation, and/or a trough FEV1 decrease from baseline of ≥100 mL, and/or a deterioration in SGRQ ≥4 units from baseline; b – a first moderate or severe exacerbation, and/or a trough FEV1 decrease from baseline of ≥100 mL, and/or a deterioration in CAT ≥2 units from baseline; c – a first moderate or severe exacerbation, and/or a deterioration in SGRQ ≥4 units from baseline and/or a deterioration in CAT ≥2 units from baseline and/or a TDI deterioration ≥1 unit decrease from baseline. CAT, COPD Assessment Test; CID, clinically important deterioration; FEV1, forced expiratory volume in 1 s; SAL, salmeterol; SGRQ, St George’s Respiratory Questionnaire; TDI, transition dyspnoea index; UMEC, umeclidinium; VI, vilanterol

Back to article page